Richon VM - Search Results

1

Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM. Cohen LA, et al. Among authors: richon vm. Anticancer Res. 2002 May-Jun;22(3):1497-504. Anticancer Res. 2002. PMID: 12168829

2

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. Butler LM, et al. Among authors: richon vm. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5. doi: 10.1073/pnas.182372299. Epub 2002 Aug 20. Proc Natl Acad Sci U S A. 2002. PMID: 12189205 Free PMC article.

3

Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).

Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM. Cohen LA, et al. Among authors: richon vm. Anticancer Res. 1999 Nov-Dec;19(6B):4999-5005. Anticancer Res. 1999. PMID: 10697502

4

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Richon VM, et al. Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9. doi: 10.1073/pnas.180316197. Proc Natl Acad Sci U S A. 2000. PMID: 10954755 Free PMC article.

5

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Butler LM, et al. Among authors: richon vm. Cancer Res. 2000 Sep 15;60(18):5165-70. Cancer Res. 2000. PMID: 11016644

6

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

Richon VM, Zhou X, Rifkind RA, Marks PA. Richon VM, et al. Blood Cells Mol Dis. 2001 Jan-Feb;27(1):260-4. doi: 10.1006/bcmd.2000.0376. Blood Cells Mol Dis. 2001. PMID: 11358386 Review. No abstract available.

7

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. O'Connor OA, et al. J Clin Oncol. 2006 Jan 1;24(1):166-73. doi: 10.1200/JCO.2005.01.9679. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330674

8

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP. Kutko MC, et al. Among authors: richon vm. Clin Cancer Res. 2003 Nov 15;9(15):5749-55. Clin Cancer Res. 2003. PMID: 14654560

9

Histone deacetylase inhibitors: development as cancer therapy.

Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T. Marks PA, et al. Among authors: richon vm. Novartis Found Symp. 2004;259:269-81; discussion 281-8. Novartis Found Symp. 2004. PMID: 15171260

10

Histone deacetylase inhibitors.

Marks PA, Richon VM, Miller T, Kelly WK. Marks PA, et al. Among authors: richon vm. Adv Cancer Res. 2004;91:137-68. doi: 10.1016/S0065-230X(04)91004-4. Adv Cancer Res. 2004. PMID: 15327890 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters